Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Olaratumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-06-11

Last Posted Date: 2019-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 137

Registration Number: NCT00918203

Locations: 🇨🇦
ImClone Investigational Site, Edmonton, Alberta, Canada

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Radiation: Proton Therapy
Radiation: Photon Therapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-06-05

Last Posted Date: 2020-05-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 275

Registration Number: NCT00915005

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Vorinostat
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2009-05-29

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00910000

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2009-05-21

Last Posted Date: 2017-02-24

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 46

Registration Number: NCT00906282

Locations: 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 9 locations

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Completed

Conditions: Lung Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-05-19

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 180

Registration Number: NCT00900172

Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab

Completed

Conditions: Lung Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-05-19

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 90

Registration Number: NCT00898417

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2009-05-12

Last Posted Date: 2013-08-12

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 60

Registration Number: NCT00897871

Locations: 🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

and more 17 locations

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

Phase 2

Completed

Conditions: Stage II Lymphoepithelioma of the Nasopharynx
Stage III Lymphoepithelioma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage IV Lymphoepithelioma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Stage II Squamous Cell Carcinoma of the Nasopharynx

Interventions: Drug: docetaxel
Drug: cisplatin
Drug: carboplatin
Drug: fluorouracil
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy

First Posted Date: 2009-05-11

Last Posted Date: 2021-04-06

Lead Sponsor: Stanford University

Target Recruit Count: 26

Registration Number: NCT00896181

Locations: 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Panitumumab
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2009-05-07

Last Posted Date: 2015-05-15

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 71

Registration Number: NCT00894504

Locations: 🇺🇸
Family Cancer Center, Collierville, Tennessee, United States
🇺🇸
Los Robles, Thousand Oaks, California, United States
🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States

and more 14 locations

Trial of Poor Performance Status Patients (ToPPS)

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2009-05-04

Last Posted Date: 2015-05-15

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 172

Registration Number: NCT00892710

Locations: 🇺🇸
Aventura Medical Center, Aventura, Florida, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Memorial Regional Cancer Center, Hollywood, Florida, United States

and more 24 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy